Please contact us for more information or to learn if you are eligible to participate.
Evaluate the safety and efficacy, as determined by 90-day incidence of mortality or transplant, for intravenous (IV) DUR-928 (30 mg or 90 mg) in subjects with severe alcohol-associated hepatitis, also known as severe alcoholic hepatitis, (AH) with pre-treatment Maddrey Discriminant Function (MDF) score ≥ 32 and MELD scores 21-30
Principal Investigator | Fernando Membreno, MD |
Co-PI | Frank Cimino |
Sponsor | DURECT Corporation |
Type of Trial | Interventional |